Korro Bio, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Korro Bio, Inc. (KRRO) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$150.00 thousand for the 6-month period ending 2019-06-30, per its 10-Q filed 2020-08-12.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2020-08-12
- 2019-06-30: Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month -$150.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month |
|---|---|
| 2019-06-30 | -$150.00K 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |